1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

  • April 2017
  • ID: 4883824
  • Format: PDF
  • GlobalData


Table of Contents

Search Inside

Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market


Breast cancer is a malignant neoplasm that begins in the breast tissue, which is made up of glands for milk production called lobules and the ducts that connect the lobules to the nipples. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system (ACS, 2013a).

In 2012 about 1.7 Million new cases of breast cancer were diagnosed globally, making it the most common cancer in women. Previously the majority of these incident cases occurred in developed regions (such as the US, EU and Australia) while less developed countries (including several of the assessed Southeast Asian countries) had lower incidence.

The current market for breast cancer consists of chemotherapies, hormonal therapies and targeted therapies. Herceptin is the gold standard monoclonal antibody (mAb) for the treatment of HER2-positive disease, and is prescribed in nearly all settings. Although it is available in all of the assessed countries, its use is limited in the majority of Southeast Asian countries due to affordability issues, and limitations surrounding the diagnosis of HER2 status.

Furthermore, there is currently a very high unmet need in triple negative breast cancer (TNBC). Treatment has been largely dependent on traditional chemotherapies, which are clinically limited in terms of both efficacy and toxicity. There is therefore a need for more effective treatment options that provide substantial improvement in progression-free survival and overall survival.

In South Korea, Singapore and Taiwan the continued uptake of targeted therapies and other premium branded drugs will contribute to the ACoT. The premium therapies Kadcyla and Perjeta are due to be approved in Indonesia, Thailand, Vietnam and Malaysia during the forecast period. Despite a lower level of expected usage of these drugs in these countries, they will account for a significant share of the market in terms of value due to their superior efficacy and high price.

The report “Breast Cancer Therapeutics in Southeast Asia Markets to 2022 – Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market” provides an introduction to breast cancer, detailing the etiology, tumor characteristics, epidemiology, diagnostic techniques, disease staging and typical prognoses for patients.

In depth, this report provides the following analysis -

- Provides detailed analysis of the products currently marketed for breast cancer, detailing their key characteristics, including safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, pricing, and overall competitive strength.
- Provides detailed analysis of the pipeline for breast cancer by stage of development, molecule type, program type, mechanism of action and molecular target. It also analyzes recent clinical trials in this indication by enrollment, duration and failure rate,
- Analysis of contains market forecasts for the breast cancer market, covering epidemiology, treatment usage patterns, pricing and market size for the 2015–2022 forecast period.
- Describes the major deals that have taken place in the SEA breast cancer market in recent years.


The current Southeast Asia breast cancer market contains well-established novel targeted products such as Perjeta and Kadcyla, tyrosine kinase inhibitors such as Tykerb, and CDK inhibitors such as Ibrance.
- Which drugs are used as the standard treatment in each setting of the disease?
- What are the competitive advantages of the existing novel drugs?
- Do branded therapies show continued growth, and how does their expected uptake influence the market growth over the forecast period?
There are about 1,150 active pipeline molecules. The pipeline contains a range of molecule types and molecular targets, including those that are well established in breast cancer, and novel, first-in-class therapies.
- Which molecular targets appear most frequently in the pipeline?
- There is currently no approved therapy in the TNBC setting. Are there any drugs in the pipeline to improve treatment for TNBC?
- Targets that are not currently represented by marketed products are virtually absent from the late-stage pipeline. Does the early stage pipeline have experimental molecules designed to target novel pathways?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II, at 59%, with the overall attrition rate for breast cancer standing at 85%.
- How do failure rates vary by stage of development, molecule type, and molecular target?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
The breast cancer Southeast Asian market will be valued at $2.7 billion in 2022, growing from $942.3m in 2015 at a CAGR of 16.2%.
- Despite an array of treatments being available for breast cancer, there is still an unmet need in the Southeast Asian markets related to low uptake of targeted therapies. Will this scenario change during the forecast period?
Market forecasts indicate that South Korea will continue to be the largest market in Southeast Asia, due to the emergence of novel therapies and the continued uptake of branded therapies.
- How will the annual cost of therapy and market size vary between the eight Southeast Asian markets?
- What are the factors that contribute to the increase in ACoT and market size for each of the assessed countries?
- How will branded therapies be affected by upcoming pipeline therapies in each of the assessed countries?
- How will the potential launch of biosimilars influence each country?
- Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?
Various drivers and barriers will influence the market over the forecast period.
- What barriers limit the uptake of premium-priced therapeutics in the assessed countries?
- What factors are most likely to drive the market in these countries?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
- Visualize the composition of the breast cancer market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are also highlighted to allow a competitive understanding of gaps in the market.
- Analyze the breast cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict breast cancer market growth in the eight Southeast Asian markets, with epidemiological and annual cost of therapy forecasts, as well as analysis of the contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the breast cancer deals landscape by analyzing trends in licensing and co-development deals.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Breast Lesion Localization Methods Market By Type, Usage, End User Preference Survey - Global Forecast to 2025

  • $ 4950
  • July 2020
  • 157 pages

The increasing incidence of breast cancer, rising awareness about benefits of early diagnosis and number of breast cancer surgeries are expected to drive the overall growth of the breast lesion localization ...

  • United States
  • Europe
  • Breast Cancer
  • Magnetic Resonance Imaging
  • Industry analysis
  • Breast Screening Coverage
  • Health Expenditure


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on